Study of golidocitinib for skin lymphoma and large granular lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an investigational pill called golidocitinib for two rare blood cancers: mycosis fungoides/Sézary syndrome (types of skin lymphoma) and T-cell large granular lymphocytic leukemia (a slow-growing leukemia). If you have one of these conditions and have already tried at least one treatment, you may be eligible to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mycosis fungoides or Sézary syndrome (stage IB to IVB) or T-cell large granular lymphocytic leukemia (T-LGLL).
- You have already had at least one previous systemic treatment for your condition.
- For T-LGLL, you must be needing treatment, such as for anemia, low platelets, or repeated infections.
- You must be able to take pills by mouth.
- You must be 18 years or older and able to follow the study schedule.
- Your blood counts, kidney, and liver function must be within study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This trial tests a new targeted pill (golidocitinib) combined with two standard chemotherapy drugs (gemcitabine and oxaliplatin, known as GemOx) for people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and works better than current options.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
Hear when a new Mycosis Fungoides/Sezary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.